Drug Research
Aptar Pharma names Jean-Marc Pardonge as prescription division new president
Aptar Pharma, a subsidiary of Aptargroup, has named Jean-Marc Pardonge as the new president for the company's prescription division. The company is involved in developing and manufacturing nasal and pulmonary drug delivery devices. In...
Drug Research
FDA approves ThromboGenics vitreomacular adhesion therapy
The USFDA has approved ThromboGenics' Jetrea (ocriplasmin) for the treatment of symptomatic vitreomacular adhesion (VMA). The approval was based on the Phase III trial data which demonstrated that Jetrea is superior to placebo for...
Drug Research
University of Utah develops 90-day intravaginal ring for HIV drug delivery
University of Utah, in collaboration with CONRAD, has developed an intravaginal ring that delivers water soluble drug, tenofovir (TFV), for 90 days to prevent HIV infection. The intravaginal reservoir ring is composed in part...
Drug Research
USPTO grants NOA to Arrowhead’s new DPC siRNA delivery system
The US Patent and Trademark Office (USPTO) has granted a notice of allowance (NOA) to Arrowhead Research's new formulation of dynamic polyconjugate (DPC) siRNA delivery system. The patent application No.13/032,029 covers claims for protecting...
Drug Research
VentiRx, Celgene to develop cancer drug
 VentiRx Pharmaceuticals has formed a world-wide collaboration with Celgene Corporation to develop VTX-2337, a highly potent and selective TLR8 agonist for cancer treatment. As part of the agreement, Celgene will fund $35m as upfront...
Drug Research
Atreca uses Immune Repertoire Capture technology to develop new vaccines
Atreca and Bill & Melinda Gates Foundation have collaborated to accelerate the discovery and development of new vaccines and therapeutics for human infectious diseases using Immune Repertoire Capture technology. Under the terms of the...
Drug Research
US FDA approves Mylan Valsartan and Hydrochlorothiazide tablets
Mylan Pharmaceuticals, a subsidiary of Mylan, has received final approval from the US Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Valsartan and Hydrochlorothiazide Tablets USP. The product is...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
